## Abstract Prostateβspecific antigen (PSA), as measured in peripheral blood, is currently the most widely used marker for the assessment of tumor burden in the longitudinal study of patients with carcinoma of the prostate (PCA). Studies from other laboratories have led to the conclusion that a giv
Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate
β Scribed by T. Malati; G. Rajani Kumari; P. V. L. N. Murthy; Ch. Ram Reddy; B. Surya Prakash
- Publisher
- Association of Clinical Biochemistry of India
- Year
- 2006
- Tongue
- English
- Weight
- 134 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0970-1915
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Background. Prostate specific antigen (PSA) does not appear to have the specificity to distinguish between benign prostate hyperplasia and cancer when the PSA is low. PSA density is thought by many to improve the specificity for cancer; however, this theory remains controversial. Methods. The autho
T1, 2, 3pN0, M0), 44 patients with BPH, and 54 healthy Charite Β΄, Humboldt University Berlin, Berlin, Gercontrols. Prostate volume was determined by transrectal ultrasound. many. ## RESULTS. The median values of t-PSA and f-PSA% were 7.8 mg/L and 10.5% in PCa patients, 4.3 mg/L and 20.8% in patie
ated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA)